Free mycophenolic acid exposure for therapeutic drug monitoring in paediatric lupus nephritis: associations with treatment response and haematologic toxicity
Open Access
- 1 July 2026
- journal article
- Published by BMJ in Lupus Science & Medicine
- Vol. 13 (2) , e002091
Abstract
Objective: This study aimed to evaluate the associations of free mycophenolic acid (f-MPA) concentration and total MPA (t-MPA) concentration with treatment response and haematologic toxicity and to determine whether f-MPA provides additional safety-related value for therapeutic drug monitoring (TDM) in patients with paediatric lupus nephritis (LN) treated with mycophenolate mofetil (MMF). Methods: Sixty-five patients with paediatric LN receiving MMF were prospectively enrolled. The t-MPA and f-MPA were measured simultaneously using validated ultrafiltration and LC-MS/MS. Full pharmacokinetic profiles were obtained over 12 hours, and area under the concentration-time curve (AUC) was calculated for t-MPA (t-MPA-AUC) and f-MPA (f-MPA-AUC). Univariate analysis identified factors influencing efficacy (relapse-free survival) and adverse drug reaction (ADR) over 12 months. Receiver operating characteristic (ROC) curves established predictive thresholds and Kaplan-Meier methods analysed time-to-event. Results: The 12-month relapse-free rate was 78.7% (95% CI 66.6% to 90.9%). Both t-MPA-AUC and f-MPA-AUC significantly correlated with relapse-free survival (ROC AUC 0.70 each; optimal thresholds: t-MPA-AUC=31.63 µg·h/mL, f-MPA-AUC=354.45 ng·h/mL). The average remission duration above these thresholds was 10.88 and 11.00 months. The overall MMF-related ADR incidence was 25.2%, including 17 haematological events (26.2%). The t-MPA-AUC, f-MPA-AUC, glucose, β2-microglobulin and C3 were haematological ADR risk factors. The f-MPA-AUC independently predicted haematological ADRs (optimal threshold: 492.96 ng·h/mL; specificity 86.2%). Conclusion: Both t-MPA-AUC and f-MPA-AUC effectively predict MMF efficacy in paediatric LN. However, f-MPA-AUC demonstrates superior predictive value for safety outcomes, specifically haematological ADRs. This supports f-MPA as a potentially better TDM metric for optimising MMF therapy safety in this population.Keywords
Funding Information
- Chronic Disease Management Research Project of National Health Commission Capacity Building and Continuing Education Center (GWJJMB202510025012)
- Research project on high quality development of Hospital pharmacy, National institute of Hospital Administration, NHC, China (NIHAYS2505)
- Research Project established by Chinese Pharmaceutical Association Hospital Phamacy Department (CPA-Z05-ZC-2025002)
- China Higher Education Institution Industry-University-Research Innovation Fund (2025XH101)
This publication has 53 references indexed in Scilit:
- Clinical manifestations, prognosis, and treat-to-target assessment of pediatric lupus nephritisPediatric Nephrology, 2021
- Validated LC–MS/MS method for quantitation of total and free mycophenolic acid concentration and its application to a pharmacokinetic study in pediatric renal transplant recipientsBiomedical Chromatography, 2020
- Kidney outcomes for children with lupus nephritisPediatric Nephrology, 2020
- Twelve-month outcome in juvenile proliferative lupus nephritis: results of the German registry studyPediatric Nephrology, 2020
- Long‐Term Clinical Outcomes in a Cohort of Adults With Childhood‐Onset Systemic Lupus ErythematosusArthritis & Rheumatology, 2019
- Regression and Genomic Analyses on the Association Between Dose-Normalized Mycophenolic Acid Exposure and Absolute Neutrophil Count in Steroid-Free, De Novo Kidney Transplant RecipientsClinical Drug Investigation, 2018
- Rate of Adverse Effects of Medium- to High-Dose Glucocorticoid Therapy in Systemic Lupus Erythematosus: A Systematic Review of Randomized Control TrialsClinical Drug Investigation, 2017
- Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosusArthritis Care & Research, 2011
- Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipientsJournal of Pharmacokinetics and Pharmacodynamics, 2009
- Immunosuppressive therapy in lupus nephritis: The Euro‐Lupus Nephritis Trial, a randomized trial of low‐dose versus high‐dose intravenous cyclophosphamideArthritis & Rheumatism, 2002